Cancer Research on Prevention and Treatment    2022, Vol. 49 Issue (06) : 541-545     DOI: 10.3971/j.issn.1000-8578.2022.21.1476
Progress and Comment on Surgical Treatment of Hepatoblastoma in Children
ZHAN Jianghua1, WANG Zhiru1,2
1. Department of General Surgery, Tianjin Children’s Hospital, Tianjin 300134, China; 2. Graduate College, Tianjin Medical University, Tianjin 300070, China
Download: PDF(3464 KB)   ( 120 )   HTML ()
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract Hepatoblastoma is the most common malignant tumor of liver in childhood. The onset of hepatoblastoma is insidious and the early symptoms are not typical. It is usually found in physical examination, mainly in the right lobe, and can involve several liver lobes. The tumor volume is often large when seeking treatment. In recent years, with the advancement of surgical techniques, the use of neoadjuvant chemotherapy drugs and the establishment of MDT teams, the survival rate of children with hepatoblastoma has been greatly improved. It’s of great significance to select effective and reasonable treatment to improve the survival rate and the quality of life and reduce adverse reactions in children with hepatoblastoma. This paper reviews the progress of surgical treatment of hepatoblastoma in children.
Keywords Hepatoblastoma      Surgical treatment      Liver transplantation      MDT      Prognosis     
ZTFLH:  R726.1  
Issue Date: 16 June 2022
 Cite this article:   
ZHAN Jianghua,WANG Zhiru. Progress and Comment on Surgical Treatment of Hepatoblastoma in Children[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 541-545.
E-mail this article
E-mail Alert
Articles by authors
ZHAN Jianghua
WANG Zhiru
[1] Feng J, Polychronidis G, Heger U, et al. Incidence trends and
survival prediction of hepatoblastoma in children: a populationbased
study[J]. Cancer Commun (Lond), 2019, 39(1): 62.
[2] Lim IIP, Bondoc AJ, Geller JI, et al. Hepatoblastoma-The
Evolution of Biology, Surgery, and Transplantation[J]. Children
(Basel), 2018, 6(1): 1.
[3] Hafberg E, Borinstein SC, Alexopoulos SP. Contemporary
management of hepatoblastoma[J]. Curr Opin Organ Transplant,
2019, 24(2): 11 3-11 7.
[4] Kehm RD, Osypuk TL, Poynter JN, et al. Do pregnancy
characteristics contribute to rising childhood cancer incidence
rates in the United States?[J]. Pediatr Blood Cancer, 2018, 65(3):
[5] Yang T, Whitlock RS, Vasudevan SA. Surgical Management of
Hepatoblastoma and Recent Advances[J]. Cancers (Basel), 2019,
11 (12): 1944.
[6] 儿童肝母细胞瘤诊疗规范(2019年版)编写审定专家组. 儿童肝母
细胞瘤诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2019, 35(11 ):
2431-2434. [Compilation and Examination Expert Group for
Guidelines for the Diagnosis and Treatment of Hepatoblastoma
(2019). Guidelines for the diagnosis and treatment of
hepatoblastoma (2019)[J]. Lin Chuang Gan Dan Bing Za Zhi,
2019, 35(11 ): 2431-2434.]
[7] 廖雪莲, 蒋莎义, 杨静薇, 等. 基于甲胎蛋白临床诊断肝母细胞
瘤行新辅助化疗可行性分析[J]. 临床儿科杂志, 2021, 39(8):
596-599. [Liao XL, Jiang SY, Yang JW, et al. Feasibility of the
neoadjuvant chemotherapy for children with hepatoblastoma
diagnosed by serum alpha-fetoprotein[J]. Lin Chuang Er Ke Za
Zhi, 2021, 39(8): 596-599.]
[8] 中华医学会病理学分会儿科病理学组,福棠儿童医学发展研究中心病理专业委员会.肝母细胞瘤病理诊断专家共识[J].
中华病理学杂志, 2019, 48(3): 1 76-181. [Group of Pediatric
Pathology, Branch of Pathology, Chinese Medical Association;
Pathology Specialist Committee of Futang Research Center
of Pediatric Development. Chinese expert group consensus on
pathological diagnosis of hepatoblastoma[J]. Zhonghua Bing Li
Xue Za Zhi, 2019, 48(3): 176-181.]
[9] Meyers RL, Maibach R, Hiyama E, et al. Risk-stratified staging in
paediatric hepatoblastoma: a unified analysis from the Children's
Hepatic tumors International Collaboration[J]. Lancet Oncol,
2017, 18(1): 122-131.
[10] Becker K, Furch C, Schmid I, et al. Impact of postoperative
c omp l i c a t i o n s o n o v e r a l l s u r v i v a l o f p a t i e n t s wi t h
hepatoblastoma[J]. Pediatr Blood Cancer, 2015, 62(1): 24-28.
[11 ] Czauderna P, Haeberle B, Hiyama E, et al. The Children's Hepatic
tumors International Collaboration (CHIC): Novel global rare
tumor database yields new prognostic factors in hepatoblastoma
and becomes a research model[J]. Eur J Cancer, 2016, 52: 92-101.
[12] 蔡耀华, 黄东生, 张谊. 儿童肝母细胞瘤的不同治疗策略[J]. 中
国小儿血液与肿瘤杂志, 2020, 25(1): 53-56. [Cai YH,Huang
DS, Zhang Y. Different therapeutic strategies for hepatoblastoma
in children[J]. Zhongguo Xiao Er Xue Ye Yu Zhong Liu Za zhi,
2020, 25(1): 53-56.]
[13] 韦源, 张现伟, 张飞, 等. 肝母细胞瘤肝切除术60例临床分析
[J]. 河南外科学杂志, 2021, 27(1): 1 30-131. [Wei Y, Zhang XW,
Zhang F, et al. Clinical analysis of 60 cases of hepatectomy for
hepatoblastoma[J]. He'nan Wai Ke Xue Za Zhi, 2021, 27(1): 1 30-131.]
[14] 吴宙光, 王斌, 李守强, 等. 经导管动脉化疗栓塞术在婴幼儿
肝母细胞瘤治疗中的应用[J]. 实用癌症杂志, 2020, 35(8):
1335-1338, 1 350. [Wu ZG, Wang B, Li SQ, et al. Application
Value of Transcatheter Arterial Chemoembolization in the
Treatment of Infantile Hepatoblastoma[J]. Shi Yong Ai Zheng Za
Zhi, 2020, 35(8): 1335-1338, 1350.]
[15] Jiang Y, Zhou S, Shen G, et al. Microwave ablation combined with
transcatheter arterial chemoembolization is effective for treating
unresectable hepatoblastoma in infants and children[J]. Medicine
(Baltimore), 2018, 97(42): e12607.
[16] Bertens KA, Hawel J, Lung K, et al. ALPPS: challenging the
concept of unresectability-a systematic review[J]. Int J Surg,
2015, 13: 280-287.
[17] 姚伟, 董岿然, 肖现民, 等. 联合肝脏离断和门静脉结扎二步
肝切除术治疗儿童肝母细胞瘤一例报告[J]. 中华小儿外科
杂志, 2018, 39(8): 597-603. [Yao W, Dong KR, Xiao XM, et al.
Associating liver partition and portal vein ligation for staged
hepatectomy for hepatoblastoma:a report of one case[J]. Zhonghua
Xiao Er Wai Ke Za Zhi, 2018, 39(8): 597-603.]
[18] 董家鸿, 黄志强. 精准肝切除——21世纪肝脏外科新理念[J].
中华外科杂志, 2009, 47(21): 1 601-1605. [Dong JH, Huang
ZQ. Precise liver resection-new concept of liver surgery in 21st
century[J]. Zhonghua Wai Ke Za Zhi, 2009, 47(21): 1601-1605. ]
[19] 杨维, 任清华, 秦红, 等. 儿童肝母细胞瘤精准肝切除手术效
果评价[J]. 临床小儿外科杂志, 2020, 1 9(5): 392-397. [Yang
W, Ren QH, Qin H, et al. Evaluation of the effect of precision
hepatectomy in children with hepatoblastoma[J]. Lin Chuang
Xiao Er Wai Ke Za Zhi, 2020, 19(5): 392-397.]
[20] Yamada Y, Ohno M, Fujino A, et al. Fluorescence-Guided Surgery
for Hepatoblastoma with Indocyanine Green[J]. Cancers (Basel),
2019, 11 (8): 1215.
[21]姚伟, 董岿然, 李凯, 等. 吲哚菁绿荧光显像技术在肝母细
胞瘤精准切除手术中的应用[J]. 临床小儿外科杂志, 2019,
18(2): 1 07-111 . [Yao W, Dong KR, Li K, et al. Application of
indocyanine green fluorescence imagine technique in precise
hepatectomy for hepatoblastoma[J]. Lin Chuang Xiao Er Wai Ke
Za Zhi, 2019, 18(2): 107-111 .]
[22] Paraboschi I, De Coppi P, Stoyanov D, et al. Fluorescence imaging
in pediatric surgery: State-of-the-art and future perspectives[J]. J
Pediatr Surg, 2021, 56(4): 655-662.
[23] 赵頔, 叶进冬, 李华丽, 等. 肝脏三维可视化重建技术在儿童复
杂肝母细胞瘤肝切除术中的应用价值[J]. 临床肝胆病杂志,
2021, 37(9): 2130-2135. [Zhao D, Ye JD, Li HL, et al. Application
of liver three-dimensional visualized reconstruction technique in
hepatectomy for children with compli-cated hepatoblastoma[J].
Lin Chuang Gan Dan Bing Za Zhi, 2021, 37(9): 2130-2135.]
[24] Moosburner S, Schmelzle M, Sch?ning W, et al. Liver
Transplantation Is Highly Effective in Children with Irresectable
Hepatoblastoma[J]. Medicina (Kaunas), 2021, 57(8): 819.
[25] Hibi T, Rela M, Eason JD, et al. Liver Transplantation for
Colorectal and Neuroendocrine Liver Metastases and
Hepatoblastoma. Working Group Report From the ILTS
Transplant Oncology Consensus Conference[J]. Transplantation,
2020, 104(6): 11 31-11 35.
[26] Shi SJ, Wang DL, Hu W, et al. Ex vivo liver resection and
autotransplantation with cardiopulmonary bypass for
hepatoblastoma in children: A case report[J]. Pediatr Transplant,
2018, 22(7): e13268.
[27] Schmelzle M, Krenzien F, Sch?ning W, et al. Laparoscopic liver
resection: indications, limitations, and economic aspects[J].
Langenbecks Arch Surg, 2020, 405(6): 725-735.
[28] Akhaladze D, Merkulov N, Rabaev G. Laparoscopic-assisted
extended right hepatectomy for hepatoblastoma in a child
(Video)[J]. Surg Oncol, 2020, 34: 234-235.
[29] Wu Y, Zeng L, Qiu R, et al. Two-stage laparoscopic resection
of giant hepatoblastoma in infants combined with liver partial
partition and artery ligation[J]. World J Surg Oncol, 2021, 1 9(1): 63.
[30] 曹迪, 柳龚堡, 史雨, 等. 儿童专科医院MDT模式建设实践探索
[J]. 复旦学报(医学版), 2020, 47(4): 599-604. [Cao D, Liu GB,
Shi Y, et al. Practical exploration of multi-disciplinary team (MDT)
mode construction in children's hospital[J]. Fudan Xue Bao(Yi
Xue Ban), 2020, 47(4): 599-604.]
[31] 高阳旭, 孙青, 李辉, 等. 儿童肝母细胞瘤多学科协作模式下的
治疗效果及临床成本[J]. 北京大学学报(医学版), 2021, 53(1):
200-203. [Gao YX, Sun Q, Li H, et al. Therapeutic effect and
clinical cost of multi-disciplinary team model of hepatoblastoma
in children[J]. Beijing Da Xue Xue Bao (Yi Xue Ban), 2021,
53(1): 200-203.]
[32] Pearson KL, Hall NJ. What is the role of enhanced recovery after
surgery in children? A scoping review[J]. Pediatr Surg Int, 2017,
33(1): 43-51.
Related articles from Frontiers Journals
[1] LI Jinzhou, WANG Wenjie, YAO Yalong, MU Yanxi, CHEN Kang, SHEN Yimin, WANG Zhou, HUANG Zeping, CHEN Xiao. Development and Validation of Prognostic Nomogram Based on Negative Lymph Node Count for Patients with Gastric Signet Ring Cell Carcinoma#br#[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 923-930.
[2] HUANG Zhenghua, ZHOU Jian, LI Yufu, LIU Yanyan, ZHOU Keshu, SONG Yongping. Clinical Efficacy and Prognostic Factors of Autologous Hematopoietic Stem Cell Transplantation for Hodgkin’s Lymphoma in 38 Cases[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 952-955.
[3] XU XiaoFei, LI Yang, CHEN Lingyun, DAI Heyang, XUE Jiaojiao, LI Qingxia, . Research Progress of PNI and CONUT in Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 961-964.
[4] JIA Lijuan, ZHANG Yunqiang, ZHANG Baihong, YUE Hongyun. Expression and Clinical Significance of m6A Methylatransferase ZC3H13 in Gastric Cancer Tissues and Serum[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 792-798.
[5] SUI Daxing, WANG Xueying, ZHANG Jiaxin. A New N-staging System for Predicting Postoperative Survival of M0 Stage Inflammatory Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 799-805.
[6] LI Jinzhou, HUANG Zeping, MU Yanxi, YAO Yalong, WANG Wenjie, LIU Haipeng, LIU Jie, WANG Zhou, CHEN Xiao. Prognostic Value of Negative Lymph Nodes Count in Solid Tumors[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 843-849.
[7] ZHOU Silei, SUN Guanqun, ZENG Tanlun, CHENG Zhuo, LIANG Xijun. Expression and Prognostic Value of CK2α' in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 662-666.
[8] XIA Lili, ZHU Xinyi, ZHANG Xiwei, LI Zhengjiang, LIU Shaoyan, LU Haizhen, AN Changming. Predictive Value of Depth of Invasion of Tongue Squamous Cell Carcinoma for Cervical Lymph Node Metastasis and Prognosis[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 675-681.
[9] . Expression of MAD2L1 in Lung Adenocarcinoma and Its Effect on Immune Microenvironment[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 586-592.
[10] WANG Jue, JIN Zongrui, WANG Wei, YI Qilin, WANG Jilong, ZHU Hai, XU Banghao, GUO Ya, WEN Zhang. Prognostic Role of Immune-related Genes in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 599-605.
[11] LI Menghan, XIAO Qiong, GAO Peng, FU Yu, SUN Chenrui, SONG Yongxi. LncRNA Prognostic Risk Scoring Model for Gastrointestinal Tumors Based on TCGA Database[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 606-611.
[12] XU Shasha, HAN Xingmin. Research Advances on Application of 18F-FDG PET/CT in Clinical Diagnosis and Treatment of Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(05): 384-389.
[13] LEI Haike, LI Xiaosheng, LI Jieping, LIU Jun, XIAO Chunyan, WANG Ying, ZHANG Wei, LIU Yao, WU Yongzhong. Clinical Characteristics and Prognostic Influence Factors of Patients with AIDS-related Malignant Tumor[J]. Cancer Research on Prevention and Treatment, 2022, 49(05): 412-417.
[14] WU Fengyang, WU Qiuji, YANG Xiting, ZHONG Yahua. Clinical Features and Prognostic Factors of Adenoid Cystic Carcinoma of Head and Neck[J]. Cancer Research on Prevention and Treatment, 2022, 49(05): 427-431.
[15] ZHONG Zhenhua, FAN Fengfeng, JIANG Wenqiang, LI Zhanwen. Clinicopathological Characteristics and Prognosis of 35 Cases of Pregnancy-associated Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(05): 432-437.
Full text